The measure will identify patients with end stage diagnoses who meet any of the listed criteria for a palliative care consult
Measure Type: Process
Timely and Effective Management of Pediatric Asthma Exacerbations in the Emergency Department
This measure evaluates the timely administration of both Short-Acting Beta Agonists (SABAs) and corticosteroids within 60 minutes of ED presentation in pediatric patients aged 2 to 18 years experiencing moderate to severe asthma exacerbations. It specifically assesses the prompt delivery of SABAs in conjunction with oral, intramuscular (IM), or intravenous (IV) corticosteroids to ensure effective management of asthma symptoms.
Optimization of Short-term Dual Antiplatelet Therapy for High-risk Cerebrovascular Events
This measure assesses the proportion of adult patients who are prescribed short-term dual antiplatelet therapy upon discharge following a diagnosis of high-risk transient ischemic attack (TIA), minor non-embolic ischemic stroke, or intracranial large artery atherosclerosis. It encourages the use of evidence-based protocols to reduce the risk of recurrent stroke.
Screening for Osteoporosis for Men Aged 70 Years and Older
Percentage of male patients aged 70 years and older who had a central dual-energy X-ray absorptiometry (DXA) to screen for osteoporosis
Reporting Frequency:
This measure is reported once per reporting period
P53 Immunohistochemistry (IHC) Staining Status in Endometrial Carcinoma
Percentage of final pathology reports for endometrial biopsy, dilation and curettage (D&C) material, or hysterectomy specimen with an initial diagnosis of primary endometrial carcinoma that contain the results of P53 immunohistochemistry (IHC) staining.
Hepatocellular Carcinoma (HCC) Screening Recommendation for Patients with Cirrhosis of the Liver
Percentage of patients, aged 18 years and older, with cirrhosis of the liver, regardless of etiology, who undergo CT/CTA of the abdomen or abdomen/pelvis, MRI of the abdomen, or abdominal US in which the final report:
Mentions that patients with cirrhosis of the liver have a higher risk of developing hepatocellular carcinoma (HCC),
AND
Includes a recommendation to consider the patient for semi-annual hepatocellular carcinoma (HCC) screening/surveillance.
Use of Breast Cancer Risk Score on Mammography
The percentage of final reports for screening mammograms which include the patient’s estimated numeric risk assessment based on a valid and published model**, and appropriate recommendations for supplemental screening based on the patient’s estimated risk and documentation of the source of recommendation.
** Must be one of the models listed in the numerator instructions of this measure specification.
Incorporating results of concurrent studies into Final Reports for Bone Marrow Aspirate of patients with Leukemia, Myelodysplastic syndrome, or Chronic Anemia
The percentage of Final Bone Marrow Aspirate Reports of patients with Leukemia, Myelodysplastic syndrome, or Chronic Anemia with documentation of concurrent studies performed, their respective results, and interpretation of those results.
Low dose cancer screening recommendation for computed tomography (CT) and computed tomography angiography (CTA) of chest with diagnosis of Emphysema.
Percentage of emphysema patients, aged 50-80 at the time of service, who undergo a CT/CTA of the chest in which the Final Report:
1) Mentions that the presence of pulmonary emphysema on CT is an independent risk factor for lung cancer, AND
2) Includes a recommendation to consider the patient for low dose CT (LDCT) lung cancer screening in the future (current chest CT serves as a baseline).
Use of Structured Reporting for Urine Cytology Specimens
The percentage of Final Reports on Urine cytology specimens, for patients of any age, that utilize The Paris System (TPS) for reporting urinary cytology.